ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Clinical trials for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple therapy shows promise in shrinking advanced stomach tumors before surgery
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (anti-PD-1) and an immune booster (thymalfasin) to standard chemotherapy (SOX) before surgery can help people with stage III stomach or gastroesophageal junction cancer. About 30 adults aged 18-75 will receive the combination,…
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Zekuan Xu • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo aims to stop stomach cancer from coming back after surgery
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from returning. About 70 adults who have had their tumor removed will receive the combination for up to …
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New combo before surgery aims to boost stomach cancer outcomes
Disease control Recruiting nowThis early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or junction cancer that can be removed. The goal is to see if the combination is safe and works well enough to …
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 11, 2026 20:53 UTC